Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.

Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Keller T, Yang ZY, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC.

J Med Chem. 2014 Mar 13;57(5):2033-46. doi: 10.1021/jm401499g.

PMID:
24320933
2.

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM.

J Hepatol. 2012 Jul;57(1):24-31. doi: 10.1016/j.jhep.2011.12.029.

PMID:
22314425
3.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS.

Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007.

PMID:
24262278
4.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ.

J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003.

5.

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R.

Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033.

PMID:
19852962
6.

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.

Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G.

Expert Opin Investig Drugs. 2014 Apr;23(4):561-71. doi: 10.1517/13543784.2014.892581. Review.

PMID:
24593285
7.

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H.

Antimicrob Agents Chemother. 2013 Dec;57(12):6333-40. doi: 10.1128/AAC.02193-12.

8.

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.

Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M.

J Viral Hepat. 2015 Dec;22(12):1011-9. doi: 10.1111/jvh.12435.

PMID:
26183611
9.

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM.

Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.

PMID:
21837752
10.

Harvoni (ledipasvir and sofosbuvir) for hepatitis C.

Mullins C, Gibson W, Klibanov OM.

Nurse Pract. 2015 Nov 15;40(11):22-6. doi: 10.1097/01.NPR.0000472253.59198.1c. No abstract available.

PMID:
26474199
11.

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.

Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW.

Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989.

PMID:
22293533
12.

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.

Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, Kato D, Link JO, Cheng G, Liu X, Sakowicz R.

PLoS One. 2015 Apr 9;10(4):e0122844. doi: 10.1371/journal.pone.0122844.

13.

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.

Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC.

Antivir Ther. 2013;18(3):311-9. doi: 10.3851/IMP2415.

PMID:
23047118
14.

Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, Hernandez LE, Beno DW, Long MA, Kati WM, Bosse TD, Larson DP, Wagner R, Lanford RE, Kohlbrenner WE, Kempf DJ, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6.

15.

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.

de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H.

Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078.

PMID:
22427481
16.

NS5A inhibitors in the treatment of hepatitis C.

Pawlotsky JM.

J Hepatol. 2013 Aug;59(2):375-82. doi: 10.1016/j.jhep.2013.03.030. Review.

17.

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

Belda O, Targett-Adams P.

Virus Res. 2012 Dec;170(1-2):1-14. doi: 10.1016/j.virusres.2012.09.007. Review.

PMID:
23009750
18.
19.

Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.

Zhong M, Peng E, Huang N, Huang Q, Huq A, Lau M, Colonno R, Li L.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5731-7. doi: 10.1016/j.bmcl.2014.10.057.

PMID:
25453810
20.

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.

Nature. 2003 Nov 13;426(6963):186-9. Erratum in: Nature. 2003 Nov 20;246.

Items per page

Supplemental Content

Support Center